首次评估 Punc E11 邻居（NOPE）作为人肝癌的一种新型标志物。

First evaluation of Neighbor of Punc E11 (NOPE) as a novel marker in human hepatocellular carcinoma.

机构信息

Department of Gastroenterology and Hepatology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Department of Internal Medicine, Donau-Ries Clinic Donauworth, Donauworth, Germany.

出版信息

Cancer Biomark. 2021;30(1):75-83. doi: 10.3233/CBM-190819.

DOI:10.3233/CBM-190819

PMID:32986656

Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) is the second most common cause of cancer death worldwide and the search for clinically useful biomarkers is ongoing. Neighbor of Punc E11 (NOPE) is an established biomarker of murine HCC that remains undetectable in normal liver and at preneoplastic stages.

OBJECTIVE

The aim of our study was to evaluate the presence of NOPE in human HCC.

METHODS

Histologically confirmed HCC and corresponding non-tumor liver samples from 20 patients were analyzed for expression of NOPE using qRT-PCR and mRNA-in-situ technology in a conserved tissue context.

RESULTS

In our cohort, 30% of HCC samples were expressing NOPE which proved particularly useful in non-cirrhotic HCC samples with up to 155-fold higher expression than in adult liver. Using mRNA-in-situ technology, NOPE was clearly identified within epithelial tumor cells of NOPE positive human HCCs. In our analyzed cohort, the combination of AFP with NOPE did not reach more than 40% sensitivity while GPC-3 and NOPE were complementary to each other reaching a combined sensitivity of 85.7%.

CONCLUSIONS

This is the first characterization of NOPE as a potential biomarker for human HCC. Our results underline the value of NOPE as a complementing biomarker for human HCC.

摘要

背景

肝细胞癌（HCC）是全球癌症死亡的第二大常见原因，目前仍在寻找临床有用的生物标志物。Punc E11 邻居（NOPE）是一种已确立的鼠 HCC 生物标志物，在正常肝脏和癌前阶段均无法检测到。

目的

本研究旨在评估 NOPE 在人 HCC 中的存在。

方法

使用 qRT-PCR 和 mRNA 原位技术在保守的组织背景下分析 20 名患者的组织学证实的 HCC 和相应的非肿瘤肝样本中 NOPE 的表达。

结果

在我们的队列中，30%的 HCC 样本表达了 NOPE，这在非肝硬化 HCC 样本中特别有用，其表达水平比成人肝脏高 155 倍。使用 mRNA 原位技术，在阳性的人 HCC 上皮肿瘤细胞中明确识别出了 NOPE。在我们分析的队列中，AFP 与 NOPE 的组合敏感性不超过 40%，而 GPC-3 和 NOPE 相互补充，组合敏感性达到 85.7%。